Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Antiplatelet Therapy Clear all
Recruiting Phase 4 Interventional

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

NCT06691191
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 90 mg, Prasugrel 10 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Phase 4 Interventional

Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel

NCT02567461
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Edoxaban 60 mg, Edoxaban 30 mg, Clopidogrel 75 mg, Aspirin 81 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 25, 2026, 10:12 AM EDT
Recruiting No phase listed Observational

Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke

NCT06292117
View directory record Official record
Conditions
Ischemic Stroke, CYP2C19 Polymorphism
Interventions
CYP2C19 Genotype
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 10:12 AM EDT
Terminated Not applicable Interventional Results available

Dual Antiplatelet Therapy Adherence With Reminder App Usage

NCT05071027
View directory record Official record
Conditions
Aneurysm Cerebral (Unruptured)
Interventions
Endovascular Neurosurgery
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Not applicable Interventional Results available

XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.

NCT03218787
View directory record Official record
Conditions
Coronary Artery Lesions
Interventions
XIENCE, DAPT
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
101
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 25, 2026, 10:12 AM EDT
Withdrawn Phase 3 Interventional

Short vs Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization

NCT02433587
View directory record Official record
Conditions
Peripheral Arterial Disease, Endovascular Procedures
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 25, 2026, 10:12 AM EDT
Completed No phase listed Observational

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

NCT01582217
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

NCT00528411
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Baton Rouge, Louisiana • Baltimore, Maryland • Towson, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Not applicable Interventional Results available

Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations

NCT01651208
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Motivational Interviewing (MINT), Mailed DVD
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
Not listed
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 25, 2026, 10:12 AM EDT
Completed No phase listed Observational

Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice

NCT04568083
View directory record Official record
Conditions
Myocardial Infarction (MI)
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Up to 130 Years
Enrollment
7,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Phase 3 Interventional

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

NCT00007683
View directory record Official record
Conditions
Heart Failure
Interventions
Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 25, 2026, 10:12 AM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting

NCT00661206
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Placebo
Drug
Lead sponsor
Deutsches Herzzentrum Muenchen
Other
Eligibility
18 Years and older
Enrollment
4,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Results available

Platelet Inhibition in Patients With Systolic Heart Failure

NCT01765400
View directory record Official record
Conditions
Systolic Heart Failure
Interventions
Prasugrel 10 mg daily x 2 weeks, Clopidogrel 75 mg daily x 2 weeks
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
View directory record Official record
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 25, 2026, 10:12 AM EDT
Enrolling by invitation No phase listed Observational

Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)

NCT06433622
View directory record Official record
Conditions
Traumatic Intracranial Hemorrhage
Interventions
Repeat Thromboelastography with Platelet Mapping
Diagnostic Test
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Crossover Trial of Clopidogrel and Ticagrelor

NCT03161678
View directory record Official record
Conditions
Myocardial Infarction, Thrombosis, Platelet Dysfunction
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Polypill in Acute Coronary Syndrome

NCT05514938
View directory record Official record
Conditions
Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
Interventions
Polypill, Usual Care (individual medications prescribed by primary cardiologist)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

NCT02217501
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Clopidogrel, Acetylsalicylic acid (ASA)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Denver, Colorado • Davenport, Iowa • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PPI and Clopidogrel Response

NCT01170533
View directory record Official record
Conditions
Drug Interaction
Interventions
omeprazole and pantoprazole
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Results available

EVOLVE Short DAPT Study

NCT02605447
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
89
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease

NCT02370680
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Aspirin, Durlaza™
Drug
Lead sponsor
New Haven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 25, 2026, 10:12 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

GM03 - Platelet RNA Signatures of Aspirin

NCT05278637
View directory record Official record
Conditions
Platelet Aggregation Inhibitors, Aspirin, Ticagrelor, RNA
Interventions
Aspirin, Ticagrelor
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 25, 2026, 10:12 AM EDT
Terminated No phase listed Observational

Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study

NCT00995514
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
4,471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 25, 2026, 10:12 AM EDT
Completed No phase listed Observational

The xDAPT External Validation Study

NCT06736626
View directory record Official record
Conditions
Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
Percutaneous coronary intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 25, 2026, 10:12 AM EDT